- Home
- QNST vs GYRE Comparison
QNST vs GYRE Comparison
Compare QNST & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNST
- GYRE
- Stock Information
- Founded
- QNST 1999
- GYRE 2002
- Country
- QNST United States
- GYRE United States
- Employees
- QNST N/A
- GYRE N/A
- Industry
- QNST Business Services
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- QNST Consumer Discretionary
- GYRE Health Care
- Exchange
- QNST Nasdaq
- GYRE Nasdaq
- Market Cap
- QNST 1.3B
- GYRE 1.3B
- IPO Year
- QNST 2010
- GYRE N/A
- Fundamental
- Price
- QNST $21.17
- GYRE $10.70
- Analyst Decision
- QNST Strong Buy
- GYRE
- Analyst Count
- QNST 6
- GYRE 0
- Target Price
- QNST $28.17
- GYRE N/A
- AVG Volume (30 Days)
- QNST 352.5K
- GYRE 132.4K
- Earning Date
- QNST 02-05-2025
- GYRE 11-13-2024
- Dividend Yield
- QNST N/A
- GYRE N/A
- EPS Growth
- QNST N/A
- GYRE N/A
- EPS
- QNST N/A
- GYRE N/A
- Revenue
- QNST $768,810,000.00
- GYRE $105,033,000.00
- Revenue This Year
- QNST $66.42
- GYRE $25.32
- Revenue Next Year
- QNST $9.01
- GYRE $12.95
- P/E Ratio
- QNST N/A
- GYRE N/A
- Revenue Growth
- QNST 37.05
- GYRE N/A
- 52 Week Low
- QNST $11.22
- GYRE $8.26
- 52 Week High
- QNST $26.27
- GYRE $30.40
- Technical
- Relative Strength Index (RSI)
- QNST 43.69
- GYRE 44.21
- Support Level
- QNST $21.46
- GYRE $9.61
- Resistance Level
- QNST $22.54
- GYRE $12.58
- Average True Range (ATR)
- QNST 0.82
- GYRE 1.22
- MACD
- QNST -0.16
- GYRE 0.05
- Stochastic Oscillator
- QNST 7.14
- GYRE 31.69
About QNST QuinStreet Inc.
QuinStreet Inc focuses on marketplaces and technologies for the financial services and home services industries. It delivers measurable and cost-effective marketing results to its clients, in the form of qualified inquiries such as clicks, leads, calls, applications, or customers. It generates revenue by delivering measurable online marketing results to the clients. Its products and services are Customer Acquisition, QuinStreet Rating Platform (QRP), and CloudControlMedia.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.